Organogenesis (ORGO) Projected to Post Quarterly Earnings on Thursday

Key Points

• Organogenesis is set to release its Q2 2025 earnings report, with expectations of an earnings per share (EPS) of ($0.01) and revenue of $104.75 million.
• The company has seen a decrease in stock price, trading down by 2.3%, with a recent stock price of $4.66 and a market capitalization of $591.12 million.
• Insider activity included the purchase of 142,379 shares by Lori Freedman, increasing her holdings by 20.48% and reflecting confidence in the company's future.

Organogenesis (NASDAQ:ORGO - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Organogenesis to post earnings of ($0.01) per share and revenue of $104.75 million for the quarter. Organogenesis has set its FY 2025 guidance at EPS.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.17). The business had revenue of $86.69 million for the quarter, compared to the consensus estimate of $90.77 million. Organogenesis had a negative net margin of 3.46% and a negative return on equity of 4.00%. On average, analysts expect Organogenesis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organogenesis Price Performance

Organogenesis stock traded down $0.11 during trading hours on Friday, reaching $4.51. The stock had a trading volume of 1,549,223 shares, compared to its average volume of 817,949. The stock has a market cap of $572.09 million, a PE ratio of -26.53 and a beta of 1.76. Organogenesis has a 52 week low of $2.28 and a 52 week high of $6.71. The company has a fifty day simple moving average of $3.78 and a 200-day simple moving average of $4.00.

Analyst Ratings Changes

A number of brokerages have issued reports on ORGO. BTIG Research reissued a "buy" rating on shares of Organogenesis in a report on Tuesday, July 15th. Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 price target on shares of Organogenesis in a report on Tuesday, July 15th.

Insider Transactions at Organogenesis

In other news, insider Lori Freedman purchased 9,022 shares of the business's stock in a transaction on Friday, June 6th. The shares were acquired at an average price of $2.99 per share, with a total value of $26,975.78. Following the acquisition, the insider directly owned 846,459 shares in the company, valued at approximately $2,530,912.41. The trade was a 1.08% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last 90 days, insiders have acquired 252,264 shares of company stock valued at $725,732. 33.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Organogenesis

A hedge fund recently bought a new stake in Organogenesis stock. Strs Ohio bought a new stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 24,400 shares of the company's stock, valued at approximately $105,000. 49.57% of the stock is owned by institutional investors and hedge funds.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.